Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
Adding to the mass of previous evidence, a new paper in the NEJM. Thread from one of the authors:
In summary, for patients requiring lipid-lowering meds:
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks
In summary, for patients requiring lipid-lowering meds:
i) There is *no* evidence of cognitive impairment over the longer term
ii) The proven cardiovascular benefits of lowering LDL-C must outweigh any speculative risks